Fahr's syndrome, familial idiopathic basal ganglia calcification, and primary familial brain calcification are further names for Fahr's disease. It is a very uncommon neurological condition marked by bilateral calcifications of certain brain regions.
Fahr's disease typically affects people in their 40s and 50s, though it can also strike children or teenagers. The prevalence of the disease is lower than 1 in 1,000,000.
There is a paucity of molecular and genetic evidence about the molecular genetics of Fahr's disease. However, one of the genes responsible for idiopathic basal ganglia calcification has been identified as IBGC1. Chromosomes 8 and 2 are found to be a second locus for the genetic pathogenesis of Fahr's disease.
Each patient's symptoms are addressed specifically through treatment. Any person with Fahr's disease has an unpredictable and difficult to predict prognosis.
Fahr disease has no known specific treatments as of yet. Treatment options for this condition's symptoms, including movement problems, seizures, anxiety, depression, psychosis, and urine incontinence, include medications. Few people have reported receiving biphosphanates outside of their prescribed dosage.
The body's metabolism, particularly the serum calcium content, is disrupted by endocrine diseases, which can result in excessive calcification of brain tissue.